Mynzepli (Aflibercept)

Aflibercept, the active ingredient in Mynzepli, is a VEGF inhibitor presented as a solution for intravitreal injection use. It treats neovascular age‑related macular degeneration, diabetic macular edema and macular edema secondary to retinal vein occlusion in adult patients.

GNH USA supplies Mynzepli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Aflibercept is an anti‑VEGF agent used to manage ocular conditions driven by abnormal vascular growth and leakage.

- Neovascular age‑related macular degeneration: reduces fluid accumulation and can stabilize or improve visual acuity. - Diabetic macular edema: decreases retinal swelling and helps preserve vision. - Macular edema secondary to retinal vein occlusion: limits edema and supports visual function.

Intravitreal administration of aflibercept may be associated with ocular and systemic adverse reactions.

Common Side Effects: - Conjunctival hemorrhage: minor bleeding on the eye surface. - Increased intraocular pressure: transient rise after injection. - Floaters: visual disturbances from vitreous particles. - Eye pain: mild discomfort at injection site.

Serious or Rare Side Effects: - Endophthalmitis: severe intraocular infection requiring urgent treatment. - Retinal detachment: separation of retinal layers, a vision‑threatening emergency. - Vitreous hemorrhage: bleeding into the vitreous cavity. - Uveitis: inflammation of the uveal tract.

Before using aflibercept intravitreal injections, clinicians should consider several safety and handling precautions. - Patient assessment: evaluate for active ocular infection or inflammation before injection. - Anticoagulant therapy: assess bleeding risk and coordinate with managing physician. - Prior ocular surgery: allow appropriate healing interval before administration. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Monitoring: schedule follow‑up examinations to detect intraocular pressure changes or inflammation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Aflibercept may interact with other agents that affect ocular healing or systemic vascular processes.

Major Interactions (Avoid): - Intravitreal steroids: combined use may increase risk of elevated intraocular pressure. - Systemic anti‑VEGF therapies: concurrent use can amplify systemic VEGF inhibition and related adverse events.

Moderate Interactions (Monitor Closely): - Anticoagulants/antiplatelet drugs: may raise risk of intraocular hemorrhage. - Ocular hypotensive agents: monitor pressure changes when used together. - Systemic hypertension medications: watch for blood pressure fluctuations.